Citations

Clear

13603 citation(s) found for "_, _".

Confronting the Challenges of Prevention, Diagnosis, and Management of Donor‐Derived Coccidioidomycosis
Vikram, Holenarasipur R. , Vikram, Holenarasipur R.

Mayo Clinic

Transplant Infectious Disease | December 17, 2024 | Volume: 27 | Issue: 1 | Pages: No page available

10.1111/tid.14424 | PMID 39688595 Get It

Three‐Year Outcomes With a Supra‐Annular, Self‐Expanding Bioprosthesis and a Pericardial Wrap—The FORWARD PRO Study
Mieghem, Nicolas M. Van , Manoharan, Ganesh, Lancellotti, Patrizio , Danenberg, Haim , Scholtz, Werner , Brecker, Stephen , Ruge, Hendrik, Opdahl, Anders , Amoroso, Giovanni , Petronio, Anna Sonia , Nickenig, Georg, Harnath, Axel, Oh, Jae K. , Eisenberg, Ruth , Grube, Eberhard, Ruge, Hendrik , Van Mieghem, Nicolas M , Kornowski, Ran , Bedogni, Francesco , Windecker, Stephan , Tamburino, Corrado , Thiele, Hölger , Fiorina, Claudia , Kempfert, Jörg

Mayo Clinic

Catheterization and Cardiovascular Interventions | December 17, 2024 | Volume: 105 | Issue: 3 | Pages: 577-587

10.1002/ccd.31335 | PMID 39686582 Get It

ABSTRACTBackgroundThe self‐expanding, supra‐annular Evolut valve is an established platform for Transcatheter Aortic Valve Implantation (TAVI). Evolut PRO introduced an outer sealing wrap to mitigate paravalvular leakage. We evaluated the 3‐year clinical outcomes and valve performance of the Evolut PRO in standard clinical practice for severe aortic stenosis (AS) patients at intermediate or higher risk for surgery.MethodsThe FORWARD PRO prospective, single‐arm, multicentre, post‐market clinical study enrolled 638 patients with native aortic valve stenosis or failed surgical bioprosthetic aortic valve undergoing TAVI, at intermediate or high risk, with the Evolut PRO valve. Clinical and serial echocardiographic outcomes were followed‐up for 3 years.ResultsTAVI using Evolut PRO was attempted in 629 AS patients (implanted in 97%) (mean age 81.7 years; STS PROM score, 4.7%). At 3 years all‐cause mortality was 25.0%, disabling stroke 6.5% (all‐cause mortality or disabling stroke, 28.5%) and rate of new permanent pacemaker implantation 24.7%. Excellent valve haemodynamics were maintained (mean gradient 8.8 ± 4.7 mm Hg; mean effective orifice area 2.0 ± 0.5 cm2) at 3 years. In a paired analysis of patients with ≥ mild paravalvular leakage (PVL) at discharge, more than two‐thirds demonstrated improved PVL at 3 years. Patients with ≥ mild PVL at discharge had higher median total calcium volume than those with no/trace PVL (p < 0.001).ConclusionsIn clinical practice TAVI with the Evolut PRO valve is associated with favorable clinical outcomes and excellent haemodynamic performance out to 3 years. The observation of improvements in PVL over time warrants further research.
NCCN Guidelines® Insights: Survivorship, Version 2.2024
Sanft, Tara , Goldman, Mindy, Ansbaugh, Shannon, Fairman, Nathan, Feliciano, Josephine , Flores, Tessa , Gabel, Nicolette , Hill‐Kayser, Christine E. , Koura, Divya, McDonough, Allison L. , Melisko, Michelle , Mooney, Kathi , Moryl, Natalie , Neuman, Heather B. , Patel, Chirayu G. , Peterson, Lindsay L. , Porpiglia, Andrea S., Schapira, Lidia , Ah, Diane Von , Wake, Robert, Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Tevaarwerk, Amyé , Day, Andrew T. , Armenian, Saro H. , Baker, Kevin Scott , Ballinger, Tarah Jean , Demark‐Wahnefried, Wendy , Friedman, Debra L. , Lee, Kimberley T. , Lee, Nita Karnik , Moore, Halle C. F. , Overholser, Linda , Pirl, William F. , Schwartz, Anna L. , Smith, Sophia K. , Yang, Eric H. , Ah, Diane Von

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 16, 2024 | Volume: 22 | Issue: 10 | Pages: 648-658

10.6004/jnccn.2024.0062 | PMID 39689426 Get It

The NCCN Guidelines for Survivorship include recommendations for screening, evaluation, and treatment of psychosocial and physical problems resulting from adult-onset cancer and its treatment. They also include recommendations to promote healthy behaviors and immunizations in survivors and provide a framework for care coordination. These NCCN Guidelines Insights summarize the panel’s current recommendations regarding sexual health and fertility.
Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology
Gupta, Samir , Axell, Lisen, Burke, Carol A. , Chen, Lee-may, Chung, Daniel C. , Clayback, Katherine M, Felder, Seth , Giardiello, Francis M., Gustafson, Susan, Hagemann, Andrea R. , Hall, Michael J. , Idos, Gregory , Joseph, Nora, Kassem, Nawal , Kelly, Kaitlyn, Kieber‐Emmons, AnnMarie, Kupfer, Sonia S., Lang, Katie, Llor, Xavier , Markowitz, Arnold J. , Prats, Mariana Moreno, Niell‐Swiller, Mariana, Pirzadeh‐Miller, Sara , Samadder, N. Jewel , Shibata, David , Swanson, Benjamin , Szymaniak, Brittany M. , Welborn, Jeanna, Wiesner, Georgia L. , Yurgelun, Matthew B. , Dwyer, Mary A., Darlow, Susan, Diwan, Zeenat, Samadder, Niloy Jewel, Gupta, Samir , Burke, Carol A , Hodan, Rachel , Weiss, Jennifer M. , Chung, Daniel C., Foda, Zachariah H. , Grady, William M. , Hampel, Heather , Katona, Bryson W , Outlaw, Darryl Alan , Stanich, Peter P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 16, 2024 | Volume: 22 | Issue: 10 | Pages: 695-711

10.6004/jnccn.2024.0061 | PMID 39689429 Get It

Multigene panel testing has allowed for the detection of a growing number of inherited pathogenic/likely pathogenic variants in people at high risk of cancer, including endometrial cancer (EC). Hereditary syndromes associated with EC include Lynch syndrome, PTEN hamartoma tumor syndrome, and Peutz-Jeghers syndrome. This manuscript provides the latest recommendations from the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric on the screening and management of EC in patients at high risk for these syndromes, as well as the advantages and limitations of multigene panel testing. This manuscript also describes recent updates to these guidelines regarding de-implementation of colon cancer screening in individuals with CHEK2 pathogenic/likely pathogenic variants, based on the most up-to-date evidence regarding the association between CHEK2 pathogenic/likely pathogenic variants and colon cancer risk.
Advancing kidney transplantation in black patients: a genetics-based and personalized approach under NICE, KDIGO, and ERBP guidelines
Cheungpasitporn, Wisit , Rivera, Franco H. Cabeza , Makkeyah, Yahya , Malik, Shafi , Vaitla, Pradeep , Fülöp, Tibor, Cheungpasitporn, Wisit , Ali, Hatem , Pethő, Ákos Géza

Mayo Clinic

Renal Failure | December 15, 2024 | Volume: 46 | Issue: 2 | Pages: No page available

10.1080/0886022x.2024.2438856 | PMID 39676231 Get It

Mn RETAIN: An early intervention model to identify and support stay at work and return to work for injured and ill employees across industries
Breeher, Laura E. , Omondi, Nancy, Westphal, Samantha, Idossa, Lensa, Green, Tammy, Connell, John, Zabel, Erik W., Trihey, Jakki, Carlson, Amy J., Apaloo, Rita, Sherrard, Cameron, Shahriar, Arif, Valappil, Usha, Pratt, Akiatu, Liedke, Angela, Carlson, Paul J. , Kohlnhofer, Stacy, Jerde, Laura, Cowl, Clayton T. , Breeher, Laura , Westphal, Samantha, Idossa, Lensa, Green, Tammy, Shahriar, Arif, Pratt, Akiatu, Carlson, Pam

Mayo Clinic

WORK: A Journal of Prevention, Assessment & Rehabilitation | December 14, 2024 | Volume: 80 | Issue: 3 | Pages: 1415-1424

10.1177/10519815241290331 | PMID 40297873 Get It

Background The Minnesota Retaining Employment and Talent After Injury and Illness Network (MN RETAIN) is a randomized controlled study designed to evaluate early interventions promoting workforce retention among workers in Minnesota. The study compares a cohort receiving increased support for stay at work and return to work (SAW/RTW) services from healthcare organizations and resources through workforce development to a control cohort provided solely a list of SAW/RTW resources within the state they can access on their own. Objective This manuscript aims to describe the design of the MN RETAIN Phase 2 study and experience to date including enrollment. Target enrollment for Phase 2 of MN RETAIN is 3200 workers with approximately half receiving SAW/RTW services from a Return-to-Work Case Manager (RWTCM) who is embedded within the healthcare team. MN RETAIN is structured to be accessible to all workers within the state, with a focus on equity and reaching historically underserved populations. Methods Phase 2 of the RETAIN model expanded the focus from the southeast region of MN to state-wide coverage. Enrollment and services were designed to acquire a large enough cohort to reach adequate statistical power to detect differences in disability costs and rates of SAW/RTW in participating study subjects. Impact analysis of RETAIN will be performed by the federal evaluator at a future date. Results Characteristics of enrolled participants to date are summarized as well as considerations for sustainability of the program upon study completion. Conclusions To date, the study has reached diverse workers from throughout the state of MN to provide assistance with SAW/RTW.
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Shroff, Rachna T. , King, Gentry Teng , Colby, Sarah, Scott, Aaron J. , Borad, Mitesh J. , Goff, Laura W. , Matin, Khalid , Mahipal, Amit , Kalyan, Aparna, Javle, Milind , Dika, Imane El , Tan, Benjamin , Cheema, P. , Iyer, Renuka , Kelley, Robin Kate , Thumar, Jaykumar , Guthrie, Katherine A. , Chiorean, E. Gabriela , Höchster, Howard S. , King, Gentry , Javle, Milind M , Cheema, Puneet S , Patel, Anuj , Iyer, Renuka , Kelley, R Katie , Thumar, Jaykumar , El-Khouiery, Anthony B , Chiorean, E Gabriela , Hochster, Howard , Philip, Philip , Mahipal, Amit , Borad, Mitesh J , Patel, Anuj , El-Khoueiry, Anthony B. , Philip, Philip A.

Mayo Clinic

Journal of Clinical Oncology | December 13, 2024 | Volume: 43 | Issue: 5 | Pages: 536-544

10.1200/jco-24-01383 | PMID 39671534 Get It

PURPOSE SWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs). METHODS Patients with newly diagnosed locally advanced unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) and gallbladder carcinoma (GBC), were randomly assigned 2:1 to either GAP (gemcitabine 800 mg/m 2 , cisplatin 25 mg/m 2 , and nab-paclitaxel 100 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle) or GC (gemcitabine 1,000 mg/m 2 and cisplatin 25 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle). RESULTS Among 452 randomly assigned participants, 441 were eligible and analyzable, 67% with ICC, 16% with GBC, and 17% with ECC. There was no significant difference in overall survival (OS) between GAP versus GC. Median OS with GAP was 14.0 months (95% CI, 12.4 to 16.1) and 13.6 months with GC (95% CI, 9.7 to 16.6); hazard ratio (HR), 0.91 (95% CI, 0.72 to 1.14); P = .41. Median progression-free survival (PFS) was similar between groups with median PFS for GAP being 7.5 months (95% CI, 6.4 to 8.5) versus 6.3 months for GC (95% CI, 4.4 to 8.2); HR, 0.89 (95% CI, 0.71 to 1.12); P = .32. In exploratory subset analyses, the OS and PFS benefits of GAP versus GC treatment were greater in locally advanced disease compared with metastatic disease, although not statistically significant (interaction P = .14 for OS and P = .17 for PFS). Moreover, GAP versus GC showed greater improvement in PFS among participants with GBC than those with ICC or ECC (interaction P = .01), but not OS (interaction P = .28). CONCLUSION The addition of a taxane in the GAP regimen to the standard gemcitabine-cisplatin regimen did not improve OS in newly diagnosed BTC. More toxicity was encountered with GAP versus GC.
Aerodigestoscopy (ADS): The Feasibility, Safety, and Comfort of a Comprehensive Procedure for the Evaluation of Physiological Disorders of the Aerodigestive Tract
Arnold, Robert , Bausek, Nina , Gaskill, Christopher S. , Johnson, Lawrence F., Aldarondo, Sigfredo, Aull, Cody, Midani, Malik , Midani, Tarek , Midani, Ramiz, Brown, Ashton S., Wallace, Alana, Arnold, Robert J , Gaskill, Christopher S , Bausek, Nina

Mayo Clinic

Journal of Clinical Medicine | December 13, 2024 | Volume: 13 | Issue: 24 | Pages: 7578

10.3390/jcm13247578 | PMID 39768501 Get It

Background: Limited access to the comprehensive assessment of disorders of the upper aerodigestive tract is a barrier to care in rural health facilities. Assessment of the full aerodigestive tract requires a variety of specialists. The inability to access the necessary specialists can result in misdiagnosis, underdiagnosis, and increased associated mortality. Currently, no single differential diagnostic exam comprehensively assesses all functions of the upper aerodigestive tract to bridge this gap. The purpose of this study is to investigate the feasibility and safety of a novel procedure called ADS that can bridge this gap. Methods: Results from 18,464 ADS procedures were retrospectively analyzed for feasibility, safety and comfort. Results: 96.8% of ADS procedures were successfully completed without complication, confirming the efficacy of the procedure. Conclusions: ADS is a single procedure for the assessment of physiological functions of the upper aerodigestive tract, including swallow, voice, respiration, and cough while also screening for impaired gastric retention and obstructive sleep apnea, which may pose additional urgent and emergent airway threats. ADS may improve health outcomes in underserved populations, e.g., those in a rural community, referred to by other health professionals due to complaints of aerodigestive symptoms and signs.
Low Income, Younger Age, Female Sex, and Poor Mental Health Are Risk Factors for Diminished Access to Care Among Patients With Meniscus Tears
Barron, Drew W., Gill, Vikram S. , Beckett, Nathan , Tummala, Sailesh V. , Chhabra, Anikar , Kraus, Drew Barron , Boddu, Sayi P. , Beckett, Nathan C, Barron, Drew W. , Chhabra, Anikar , Tummala, Sailesh V , Barron, Drew W.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | December 12, 2024 | Volume: 7 | Issue: 2 | Pages: No page available

10.1016/j.asmr.2024.101064 | PMID 40297065 Get It

Purpose To use the All of Us database to investigate barriers to health care access for patients with meniscus tears and to examine how specific demographic, socioeconomic, and health‐related factors independently influence their health care utilization. Methods The National Institutes of Health All of Us database was queried for patient data between March 2017 and March 2023 to form a cohort of patients with meniscal tears. Patients with meniscal tears were identified using Systematized Nomenclature of Medicine clinical terms. All patients with self‐reported meniscus tears were included, with no exclusion criteria to ensure a diverse representation of underrepresented individuals. Patient responses to the “Healthcare Access and Utilization Survey” were analyzed across 4 domains: “delayed care,” “could not afford care,” “skipped medication,” and “have not seen a provider in over one year.” Results In total, 5,671 survey respondents with meniscal tears were included for analysis from a population of 436,000 eligible records. Among them, 27.7% reported delayed care, 23.9% were unable to afford care, 11.8% skipped medication, and 2.0% had not seen a provider in over a year. Patients with annual incomes under $50,000 were more likely to delay care (odds ratio [OR], 1.41; P < .001), be unable to afford care (OR, 1.73; P < .001), or skip medications (OR, 1.79; P < .001). Younger age than the cohort mean of 65.4 years, female sex, and poor physical and mental health were associated with impaired access in at least 1 care domain. Conclusions Over one‐fourth of patients with a diagnosis of meniscus tear who responded to the All of Us “Healthcare Access and Utilization Survey” reported difficulties with access to care across 4 domains, with those of low income, younger age, female sex, and poor mental or physical health experiencing significant barriers to care. Clinical Relevance This research can inform strategies for equitable treatment of meniscal injuries by highlighting disparities in orthopaedic care access and utilization.
Associations Between Maternal Periconceptional Alcohol Consumption and Risk of Craniosynostosis Among Offspring, National Birth Defects Prevention Study, 1997–2011
Fisher, Sarah C. , Romitti, Paul A. , Howley, Meredith M. , Browne, Marilyn L. , Study, the National Birth Defects Prevention, Howley, Meredith M , Jabs, Ethylin Wang, Browne, Marilyn L , Tracy, Melissa , Jabs, Ethylin W , Study, the National Birth Defects Prevention

Mayo Clinic

Birth Defects Research | December 12, 2024 | Volume: 116 | Issue: 12 | Pages: No page available

10.1002/bdr2.2420 | PMID 39665132 Get It

ABSTRACTBackgroundPrevious studies of maternal alcohol consumption and craniosynostosis have reported null or inverse associations. We updated a previous analysis of National Birth Defects Prevention Study (NBDPS) data to further examine associations between maternal alcohol consumption and craniosynostosis.MethodsNBDPS was a multi‐site, population‐based case–control study. Mothers of craniosynostosis cases and randomly selected liveborn controls delivered during 1997–2011 completed a telephone interview about pregnancy exposures. We examined associations for self‐reported periconceptional maternal alcohol consumption (during the month before conception through the third gestational month) and odds of craniosynostosis in offspring. We used logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between any alcohol consumption and binge consumption and craniosynostosis, overall and by affected suture. Finally, we performed a probabilistic bias analysis using a range of assumptions about the sensitivity and specificity of self‐reported consumption by case/control status.ResultsWe analyzed interview data from 1435 mothers of craniosynostosis cases and 11,216 mothers of controls. Periconceptional alcohol consumption prevalence was similar among case (36.9%) and control (38.2%) mothers. We observed point estimates near or below 1.0 for alcohol consumption (any and binge) and all suture subtypes of craniosynostosis, with all CIs including the null. Our bias‐adjusted estimates for periconceptional alcohol consumption were higher than our conventional estimates but supported the null findings.ConclusionsWe observed primarily null associations between maternal periconceptional alcohol consumption and craniosynostosis. However, our findings do not diminish the prevailing clinical guidance in the United States that pregnant people should abstain from alcohol consumption.